Trial
NCT01400451
Ph I Ipilimumab Vemurafenib Combo in Patients With v-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF)
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Bristol-Myers Squibb
Collaborators
Roche-Genentech
Condition
Melanoma
Intervention
Ipilimumab (BMS-734016)
Why stopped
More than 2 of 6 patients treated experienced dose limiting toxicities.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2015-01-01